Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Small caliber arterial endothelial cells calcium signals elicited by PAR2 are preserved from endothelial dysfunction.

Hennessey JC, Stuyvers BD, McGuire JJ.

Pharmacol Res Perspect. 2015 Mar;3(2):e00112. doi: 10.1002/prp2.112.

2.

Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.

Kagota S, Maruyama K, Wakuda H, McGuire JJ, Yoshikawa N, Nakamura K, Shinozuka K.

Vascul Pharmacol. 2014 Oct;63(1):46-54. doi: 10.1016/j.vph.2014.06.005. Epub 2014 Aug 7.

PMID:
25109437
3.

Effects of chronic in-vivo treatments with protease-activated receptor 2 agonist on endothelium function and blood pressures in mice.

Hughes KH, Wijekoon EP, Valcour JE, Chia EW, McGuire JJ.

Can J Physiol Pharmacol. 2013 Apr;91(4):295-305. doi: 10.1139/cjpp-2012-0266. Epub 2012 Dec 19.

4.

Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice.

Hennessey JC, McGuire JJ.

PLoS One. 2013;8(2):e55965. doi: 10.1371/journal.pone.0055965. Epub 2013 Feb 7.

5.
6.

Geophysics. A rogue earthquake off Sumatra.

McGuire JJ, Beroza GC.

Science. 2012 Jun 1;336(6085):1118-9. doi: 10.1126/science.1223983. Epub 2012 May 10. No abstract available.

PMID:
22582017
7.

Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice.

Chia E, Kagota S, Wijekoon EP, McGuire JJ.

BMC Pharmacol. 2011 Sep 28;11:10. doi: 10.1186/1471-2210-11-10.

8.

Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice.

Kagota S, Chia E, McGuire JJ.

Br J Pharmacol. 2011 Sep;164(2):358-71. doi: 10.1111/j.1476-5381.2011.01356.x.

9.
10.

Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats.

Smeda JS, McGuire JJ, Daneshtalab N.

Peptides. 2010 Feb;31(2):227-37. doi: 10.1016/j.peptides.2009.11.026. Epub 2009 Nov 30.

PMID:
19954757
11.

Inhibition of human folylpolyglutamate synthetase by diastereomeric phosphinic acid mimics of the tetrahedral intermediate.

McGuire JJ, Bartley DM, Tomsho JW, Haile WH, Coward JK.

Arch Biochem Biophys. 2009 Aug 15;488(2):140-5. doi: 10.1016/j.abb.2009.06.017. Epub 2009 Jun 27. Erratum in: Arch Biochem Biophys. 2010 Jan 15;493(2):250.

12.

Developmental programming of lipid metabolism and aortic vascular function in C57BL/6 mice: a novel study suggesting an involvement of LDL-receptor.

Chechi K, McGuire JJ, Cheema SK.

Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1029-40. doi: 10.1152/ajpregu.90932.2008. Epub 2009 Feb 4. Erratum in: Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R911.

13.

Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs.

McGuire JJ, Haile WH.

Biochem Pharmacol. 2009 Apr 1;77(7):1161-72. doi: 10.1016/j.bcp.2008.12.020. Epub 2009 Jan 6.

PMID:
19174154
14.
15.
16.

Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.

Gangjee A, Zeng Y, Talreja T, McGuire JJ, Kisliuk RL, Queener SF.

J Med Chem. 2007 Jun 28;50(13):3046-53. Epub 2007 Jun 7.

17.
18.

Persistence of PAR-2 vasodilation despite endothelial dysfunction in BPH/2 hypertensive mice.

McGuire JJ, Van Vliet BN, Giménez J, King JC, Halfyard SJ.

Pflugers Arch. 2007 Jul;454(4):535-43. Epub 2007 Feb 23.

PMID:
17318644
19.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk